Firalis - All Media

Home
About
Services
R&D
Products
Quality
Investors
Media
Careers
IFU APO-Easy
Copy of IFU APO-Easy
Stability APO-Easy
APO-Easy-FLS-OE02-01
APO-Easy-FLS-OE02-02
APO-Easy-FLS-OE02-03

Home
About
Services
Products
R&D
Quality
Investors
Media

All Media

Autoimmune project, PARADISE, holds first plenary to highlight six months of project progress

07.11.2023

COVIRNA Project Final Conference takes place on 19-April-23

COVIRNA Project Final Conference takes place on 19-April-23

COVIRNA Project end date is approaching, with the final conference that will take place in Brussels on the 19th of April, 2023.

07.04.2023

PARADISE Project launches with a kick-off held in Dublin (3-4 April 2023)

PARADISE Project launches with a kick-off held in Dublin (3-4 April 2023)

To develop a personalised prediction tool for better management of autoimmune diseases recurrence, PARADISE Project kicked off on 3 -4 April 2023 in Dublin, coordinated by ADAPT at Trinity College of Dublin, with partners across several European institutions, including FIRALIS.

05.04.2023

Bpifrance funds Firalis’ Alzheimer Project!

Bpifrance funds Firalis’ Alzheimer Project!

FIRALIS’ Research on Neurodegenerative Diseases obtains Bpifrance Funding!

09.08.2022

FIRALIS obtains ISO 14001 International Quality Standard !

FIRALIS obtains ISO 14001 International Quality Standard !

FIRALIS obtained the AFNOR certification “ISO 14001”, a gold standard in improving the environmental performance!

11.07.2022

Reasons for hope on World Alzheimer’s Day

Reasons for hope on World Alzheimer’s Day

21st September : World Alzheimer's Day. 📅

21.09.2021

RNAs to predict COVID-19's cardiovascular outcomes

RNAs to predict COVID-19's cardiovascular outcomes

Check out the video presentation of COVIRNA Consortium

19.07.2021

Firalis, Laureat again for its High Potential

Firalis, Laureat again for its High Potential

Trophées Alsace Export 2020 - Prizewinner in category "Corporate with High Potential"

12.05.2021

Le test Covid-19 qui fait saliver le monde !

Parution de Firalis dans le magazine régional Point Eco Alsace.

10.03.2021

EASYCOV: INAUGURATION DE LA LIGNE DE PRODUCTION

EASYCOV: INAUGURATION DE LA LIGNE DE PRODUCTION

Firalis a inauguré la ligne de production automatisée, dédiée au production de "EasyCOV", le test rapide salivaire de dépistage du Covid-19 !

09.12.2020

HAS valide le remboursement d'EasyCOV*

HAS valide le remboursement d'EasyCOV*

*La Haute Autorité de Santé (HAS) valide l’utilisation et recommande le remboursement du test salivaire EasyCOV® sous conditions.

28.11.2020

TACKLING COVID-19: THE "COVIRNA" PROJECT

TACKLING COVID-19: THE "COVIRNA" PROJECT

A diagnostic test funded by the EU, to improve surveillance and care of COVID-19 patients

27.11.2020

Olink in Covid-19 R&D

Olink in Covid-19 R&D

Outstanding Olink technology offering for COVID-19 Research

06.08.2020

EasyCov: Covid-19 saliva test

EasyCov: Covid-19 saliva test

Firalis-produced and CE-marked "EasyCOV" saliva test, developed by Skillcell

18.06.2020

Firalis and EasyCOV on DNA

Firalis and EasyCOV on DNA

Firalis and the EasyCOV test are mentioned on an article published by the "DNA" (Les Dernières Nouvelles d'Alsace).

10.05.2020

Firalis against Covid-19 !

20.03.2020

Contact Firalis

Firalis Group

© Copyright 2020 all rights reserved.

The company logos, products and service marks are trademarks or registered trademarks of Firalis.

-----------------------------------------------------------------------------------------------------------------------

Information addressed to health professionals. The products presented on this site are for professional use only and, where applicable, comply with the requirements of the IVD Directive 98/79 / EC. Instructions for use must be consulted before using these products.

-----------------------------------------------------------------------------------------------------------------------

Headquarter : 17 Rue du Fort 68330 Huningue FRANCE